Outcomes for patients with hematologic malignancy infected with COVID-19 have not been
aggregated. The objective of this study was to perform a systematic review and meta …

Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This
effect has included the adverse outcomes in patients with cancer who develop COVID-19 …

Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …

Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at
high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological
patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and …

IDSA Disclaimer As of the time of this publication, updates have been made to IDSA's
Guidelines on the Diagnosis of COVID-19. For the most updated version of these guidelines …

Methods We examined 44 consecutive patients with CLL who received two doses of mRNA
vaccine (BNT162b2 or mRNA-1273) between 1/2/21 and 3/12/21 and were tested for anti …

Patients with hematologic malignancies have an increased risk of severe COVID‐19
infection. Vaccination against COVID‐19 is especially important in these patients, but …

Abstract Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose
considerable challenges for the management of oncology patients. COVID-19 presents as a …